SCHEMBL6476569

SCHEMBL6476569

O=C(O)c1ccccc1Nc1ccc(CCc2ccc(F)c(C(F)(F)F)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
RECQL P46063 1/20 0.62
BLM P54132 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
TAS2R14 Q9NYV8 10/20 0.57
SIRT2 Q8IXJ6 1/20 0.53
PTGS1 P23219 1/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
FABP4 P15090 2/20 0.48
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
CLCN2 P51788 1/20 0.46
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
TEAD4 Q15561 1/20 0.45
HCAR2 Q8TDS4 2/20 0.45
NR3C2 P08235 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475269 0.87 MEN1 (0.74) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475047 0.87 MEN1 (0.69) MEN1KMT2ARECQLBLMTDP1
SCHEMBL4245362 0.86 TAS2R14 (0.74) TAS2R14PTGS1AKR1C3AKR1C2FABP4
SCHEMBL6475772 0.82 MEN1 (0.76) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482845 0.82 CTSV (0.57) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482926 0.81 MEN1 (0.65) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482855 0.81 SIRT2 (0.77) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482894 0.81 MEN1 (0.67) MEN1KMT2ARECQLBLMTDP1
SCHEMBL27560787 0.79 MEN1 (0.62) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6484419 0.78 MEN1 (0.75) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885RECQL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.